Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Faculty of 1000 evaluation for Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial., April 2015, Faculty of 1000, Ltd.,
DOI: 10.3410/f.725419696.793505862.
You can read the full text:
Contributors
The following have contributed to this page